Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
CLINICAL EPIDEMIOLOGY
You have accessRestricted Access

Change in Estimated GFR Associates with Coronary Heart Disease and Mortality

Kunihiro Matsushita, Elizabeth Selvin, Lori D. Bash, Nora Franceschini, Brad C. Astor and Josef Coresh
JASN December 2009, 20 (12) 2617-2624; DOI: https://doi.org/10.1681/ASN.2009010025
Kunihiro Matsushita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Selvin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori D. Bash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nora Franceschini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brad C. Astor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josef Coresh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Distribution of percentage annual change in eGFR on the basis of 3-yr change among 13,029 participants of the ARIC Study is shown. Cutoff points of quartiles were −5.65, −0.47, and −0.33%/yr.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    (A and B) Adjusted incidence rates and their 95% CIs of CHD (A) and all-cause mortality (B) are shown by quartiles of percentage annual changes in eGFR (Q1 through Q4) from visit 1 to visit 2 (3-yr change) or visit 4 (9-yr change). Cutoff points of quartiles were −5.65, −0.47, and −0.33%/yr for 3-yr change and −2.46, −0.74, and −0.56%/yr for 9-yr change. Adjusted to mean age (54.0 yr), race (white), and gender (male).

Tables

  • Figures
  • Additional Files
    • View popup
    Table 1.

    Characteristics of participants according to quartiles of change in eGFR from visit 1 to visit 2

    CharacteristicQuartiles of % Annual Change in eGFR
    Q1 (−52.76 to −5.65; n = 3258)Q2 (−5.65 to −0.47; n = 3257)Q3 (−0.47 to −0.33; n = 3257)Q4 (−0.33 to 42.94; n = 3257)
    Age (yr; mean ± SD)54.0 ± 5.853.8 ± 5.853.2 ± 5.154.9 ± 6.0
    Male gender (%)32.351.740.747.1
    Black race (%)27.825.820.424.4
    Educational level (%)a
        <12 yr completed22.420.718.422.2
        12 to 16 yr completed41.840.742.941.5
        >16 yr completed35.838.638.736.3
    Current smokers (%)a24.723.724.124.9
    Current alcohol drinkers (%)a54.457.761.157.4
    BMI (kg/m2; mean ± SD)a27.5 ± 5.527.5 ± 4.927.3 ± 5.227.9 ± 5.4
    Diabetes mellitus (%)12.28.68.011.5
    Antihypertensive medication (%)a28.526.424.929.9
    ACEI (%)a3.02.72.73.0
    SBP (mmHg; mean ± SD)a121.9 ± 20.1121.2 ± 17.8118.5 ± 16.9120.3 ± 17.5
    DBP (mmHg; mean ± SD)a73.5 ± 11.474.4 ± 10.972.8 ± 10.673.3 ± 10.7
    LDL cholesterol (mg/dl; mean ± SD)a134.0 ± 38.8137.9 ± 39.1136.9 ± 38.5138.7 ± 39.1
    HDL cholesterol (mg/dl; mean ± SD)a53.7 ± 17.351.3 ± 16.352.8 ± 17.451.4 ± 16.9
    TG (mg/dl; median [IQR])a106 (75, 152.5)107 (78, 152)106 (78, 152)113 (80, 158)
    Left ventricular hypertrophy (%)a2.42.01.22.0
    Carotid atherosclerosis (%)a8.57.45.57.0
    Serum creatinine (mg/dl; mean ± SD)
        visit 10.75 ± 0.200.87 ± 0.150.85 ± 0.170.93 ± 0.19
        visit 20.96 ± 0.470.97 ± 0.160.85 ± 0.170.84 ± 0.18
    eGFR (ml/min per 1.73 m2; mean ± SD)
        visit 1105.9 ± 23.291.5 ± 16.091.1 ± 16.984.0 ± 17.0
        visit 280.3 ± 18.580.0 ± 14.090.1 ± 16.794.3 ± 20.5
    • All comparisons were significant at P < 0.001, except for current smoking (P = 0.016), angiotensin-converting enzyme inhibitors (ACEI; P = 0.829), and left ventricular hypertrophy (P = 0.002). BMI, body mass index; SBP, systolic BP; DBP, diastolic BP; IQR, interquartile range; TG, triglycerides.

    • ↵aMissing values (number missing): Educational level, 20; current smokers, 8; current drinkers, 43; BMI, 7; diabetes, 19; antihypertensive medication, 6; ACEI, 1; SBP, 3; DBP, 4; LDL cholesterol, 258; HDL cholesterol, 84; TG, 83; left ventricular hypertrophy, 303; carotid atherosclerosis, 386.

    • View popup
    Table 2.

    Adjusted HRs (95% CIs) of CHD and all-cause death by quartiles of % annual change in eGFR from visit 1 to visit 2, overall, and eGFR category at visit 1

    OutcomesQuartiles of % Annual Change in eGFR
    Q1 (−52.76 to −5.65)Q2 (−5.65 to −0.47)Q3 (−0.47 to −0.33)Q4 (−0.33 to 42.94)
    All
        na3016301230042985
        CHD1.30 (1.11 to 1.52)1.16 (1.00 to 1.35)Reference1.04 (0.90 to 1.22)
        all-cause mortality1.22 (1.06 to 1.41)1.05 (0.92 to 1.21)Reference1.10 (0.96 to 1.27)
    eGFR ≥90 ml/min per 1.73 m2
        na226213631247826
        CHD1.13 (0.91 to 1.41)1.19 (0.95 to 1.49)Reference0.98 (0.75 to 1.28)
        all-cause mortality0.96 (0.80 to 1.16)0.93 (0.76 to 1.13)Reference1.00 (0.80 to 1.23)
    eGFR 60 to <90 ml/min per 1.73 m2
        na716160417201996
        CHD1.39 (1.09 to 1.76)1.10 (0.90 to 1.36)Reference1.06 (0.87 to 1.29)
        all-cause mortality1.40 (1.12 to 1.76)1.10 (0.90 to 1.35)Reference1.18 (0.97 to 1.42)
    eGFR 30 to <60 ml/min per 1.73 m2
        na374437163
        CHD1.47 (0.46 to 4.67)1.68 (0.56 to 4.99)reference1.16 (0.43 to 3.10)
        all-cause mortality4.69 (1.28 to 17.16)4.98 (1.36 to 18.25)reference2.52 (0.73 to 8.74)
    • Adjusted for following covariates at visit 1: Age, race, gender, level of education, carotid atherosclerosis, SBP, antihypertensive medication, diabetes, smoking, alcohol intake, BMI, LDL cholesterol, HDL cholesterol, left ventricular hypertrophy, and eGFR.

    • ↵aParticipants included in the fully adjusted analysis.

    • View popup
    Table 3.

    Adjusted HR (95% CIs) of CHD and all-cause mortality by quartiles of % annual change in eGFR from visit 1 to visit 4

    OutcomesQuartiles of % Annual Change in eGFR
    Q1 (−25.53 to −2.46)Q2 (−2.46 to −0.74)Q3 (−0.74 to −0.56)Q4 (−0.56 to 13.54)
    Adjustment for covariates at visit 1
        na2326231623392335
        CHD1.32 (1.08 to 1.63)1.06 (0.86 to 1.30)Reference1.18 (0.97 to 1.45)
        all-cause mortality1.41 (1.16 to 1.72)1.11 (0.90 to 1.36)Reference1.11 (0.90 to 1.36)
    Adjustment for covariates at visit 4
        na1190113011311048
        CHD1.17 (0.87 to 1.58)1.11 (0.84 to 1.48)Reference1.32 (0.99 to 1.74)
        all-cause mortality1.27 (0.97 to 1.67)0.98 (0.74 to 1.30)Reference1.05 (0.80 to 1.39)
    • Adjusted for following covariates at either visit: Age, race, gender, level of education, carotid atherosclerosis, SBP, antihypertensive medication, diabetes, smoking, alcohol intake, BMI, LDL cholesterol, HDL cholesterol, left ventricular hypertrophy, and eGFR.

    • ↵aParticipants included in the fully adjusted analysis.

Additional Files

  • Figures
  • Tables
  • Change in Estimated GFR Associates with Coronary Heart Disease and Mortality

    Files in this Data Supplement:

    • Press Release
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 20 (12)
Journal of the American Society of Nephrology
Vol. 20, Issue 12
1 Dec 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Change in Estimated GFR Associates with Coronary Heart Disease and Mortality
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Change in Estimated GFR Associates with Coronary Heart Disease and Mortality
Kunihiro Matsushita, Elizabeth Selvin, Lori D. Bash, Nora Franceschini, Brad C. Astor, Josef Coresh
JASN Dec 2009, 20 (12) 2617-2624; DOI: 10.1681/ASN.2009010025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Change in Estimated GFR Associates with Coronary Heart Disease and Mortality
Kunihiro Matsushita, Elizabeth Selvin, Lori D. Bash, Nora Franceschini, Brad C. Astor, Josef Coresh
JASN Dec 2009, 20 (12) 2617-2624; DOI: 10.1681/ASN.2009010025
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study
  • Long-Term Exposure to Ambient PM2.5 and Increased Risk of CKD Prevalence in China
  • Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study
Show more Clinical Epidemiology

Cited By...

  • Slope of Kidney Function and Its Association with Longitudinal Mortality and Cardiovascular Disease among Individuals with CKD
  • Is there a correlation between an eGFR slope measured over a 5-year period and incident cardiovascular events in the following 5 years among a Flemish general practice population: a retrospective cohort study
  • Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
  • APOL1 Nephropathy Risk Variants and Incident Cardiovascular Disease Events in Community-Dwelling Black Adults
  • Time-Centered Approach to Understanding Risk Factors for the Progression of CKD
  • Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study
  • Sleep and CKD in Chinese Adults: A Cross-Sectional Study
  • Past Decline Versus Current eGFR and Subsequent Mortality Risk
  • Past Decline Versus Current eGFR and Subsequent ESRD Risk
  • Change in Measured GFR Versus eGFR and CKD Outcomes
  • Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes
  • Health Education and General Practitioner Training in Hypertension Management: Long-Term Effects on Kidney Function
  • Structural Predictors of Renal Function Decline
  • Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD
  • Rate of Change in Renal Function and Mortality in Elderly Treated Hypertensive Patients
  • Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality
  • Short-Term Change in eGFR and Risk of Cardiovascular Events
  • APOL1 Variants Associate with Increased Risk of CKD among African Americans
  • More Evidence on an Abominable Pairing: Atrial Fibrillation and Kidney Disease
  • Web Surveillance for CKD
  • Vascular Disease, ESRD, and Death: Interpreting Competing Risk Analyses
  • Improvement in Kidney Function: A Real Occurrence
  • Urine Volume and Change in Estimated GFR in a Community-Based Cohort Study
  • Screening for Proteinuria: A Tool for Predicting Rapid Declines in Kidney Function?
  • Dipstick Proteinuria as a Screening Strategy to Identify Rapid Renal Decline
  • Change in Kidney Function over Time and Risk for Adverse Outcomes: Is an Increasing Estimated GFR Harmful?
  • GFR Decline and Mortality Risk among Patients with Chronic Kidney Disease
  • World Kidney Day 2011: Protect Your Kidneys, Save Your Heart
  • Prediction Modeling to Assess the Prognostic Significance of a Biomarker Panel
  • Rate of Kidney Function Decline Associates with Increased Risk of Death
  • Rate of Kidney Function Decline Associates with Mortality
  • Mechanisms of Tubulointerstitial Fibrosis
  • Prediabetes, Prehypertension ... Is It Time for Pre-CKD?
  • Google Scholar

Similar Articles

Related Articles

  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire